DFTX — Definium Therapeutics, Inc. stock price, charts and financials
QT91Definium Therapeutics, Inc.Definium Therapeutics, Inc. (NASDAQ: DFTX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
38.81
+0.13+0.34%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 16.12% | Shs Outstand | 132.74M | Perf Week | -0.21% |
| Market Cap | 5.15B | Forward P/E | - | EPS next Y | -2.02 | Insider Trans | -0.56% | Shs Float | 128.87M | Perf Month | -15.30% |
| Enterprise Value | 4.10B | PEG | - | EPS next Q | -0.54 | Inst Own | - | Short Float | 7.63% | Perf Quarter | 58.54% |
| Income | -184.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 3.30 | Perf Half Y | 107.98% |
| Sales | 0.00 | P/B | 5.61 | EPS next Y | 36.21% | ROA | -31.79% | Short Interest | 9.84M | Perf YTD | 189.84% |
| Book/sh | 6.92 | P/C | 4.75 | EPS next 5Y | - | ROE | -85.23% | 52W High | 49.70 -21.91% | Perf Year | 305.54% |
| Cash/sh | 8.17 | P/FCF | - | EPS past 3/5Y | - | ROIC | -23.81% | 52W Low | 8.77 342.53% | Perf 3Y | 858.27% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 6.64% 4.83% | Perf 5Y | 2.67% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -2193.33% | Oper. Margin | 0.00% | ATR (14) | 2.26 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.95 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 45.01 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.95 | EPS Q/Q | -188.00% | SMA20 | -2.98% | Beta | 2.19 | Target Price | 67.45 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -8.55% | Rel Volume | 1.08 | Prev Close | 38.68 |
| Employees | 106 | LT Debt/Eq | 0.09 | Earnings | Nov 05 | SMA200 | 48.51% | Avg Volume | 2.98M | Price | 38.81 |
| IPO Date | Nov 15, 2016 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -166.16% - | Net Debt/EBITDA | 1.82 | Volume | 3,210,060 | Change | 0.34% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-15-26 | Reiterated | UBS | $70 | |
| Sep-15-26 | Reiterated | Robert W. Baird | $75 → $79 | |
| Sep-15-26 | Reiterated | Canaccord Genuity | Buy | $64 → $78 |
| Sep-14-26 | Reiterated | Oppenheimer | Outperform | $70 → $75 |
| Aug-14-26 | Reiterated | Maxim Group | Buy | $55 |
| Aug-13-26 | Reiterated | Robert W. Baird | $57 → $75 | |
| Aug-13-26 | Reiterated | Canaccord Genuity | Buy | $58 → $64 |
| Aug-12-26 | Reiterated | Oppenheimer | Outperform | $60 → $70 |
| Aug-12-26 | Reiterated | Needham | Buy | $50 → $66 |
| Jul-27-26 | Initiated | Wells Fargo | Overweight | $68 |
Latest News· Times ET
Sep-15-26
Sep-14-26
Sep-14-2610:31AM
08:14AM
07:13AM
03:00AM
02:00AM
Definium Therapeutics Announces New Employee Inducement Grantsbusinesswire.com
Sep-10-26
Sep-10-2603:00AM
Sep-08-26
Sep-08-2603:08AM
03:00AM
Sep-04-26
Sep-04-2603:59PM
Aug-31-26
Aug-26-26
Aug-26-2603:01AM
Aug-18-26
Aug-18-2604:45AM
Aug-17-26
Company
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 8/31/2019 | FY 2018 8/31/2018 | FY 2017 8/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 1 | 3 | — | — | — | — | — | — | |
| Gross Profit | 0 | -1 | -3 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 49 | 39 | 42 | — | — | — | — | — | — | |
| Research and Development | 118 | 65 | 49 | — | — | — | — | — | — | |
| Other Operating Expense | -1 | -1 | 0 | — | — | — | — | — | — | |
| Operating Income | -166 | -104 | -94 | — | — | — | — | — | — | |
| Interest Expense | 5 | 2 | 1 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -12 | -2 | -1 | — | — | — | — | — | — | |
| Net Income Before Taxes | -184 | -109 | -96 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -184 | -109 | -96 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -184 | -109 | -96 | — | — | — | — | — | — | |
| Net Income | -184 | -109 | -96 | — | — | — | — | — | — | |
| EPS (Recurring) | -2.06 | -1.54 | -2.44 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.06 | -1.54 | -2.44 | — | — | — | — | — | — | |
| EPS (Diluted) | -2.06 | -0.15 | -2.44 | — | — | — | — | — | — | |
| EBITDA | -178 | -106 | -93 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 89 | 70 | 39 | — | — | — | — | — | — | |
| Market Capitalization | 1,192 | 487 | 143 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Barrow Robert | Chief Executive Officer | Sep 03 '26 | Sale | 37.94 | 19,023 | 721,733 | 1,494,640 | Sep 04 |
| Sullivan Mark | Chief Legal Officer | Jun 25 '26 | Sale | 45.03 | 13,008 | 585,750 | 320,571 | Jun 26 |
| Roberts Brandi | Chief Financial Officer | Jun 25 '26 | Sale | 45.03 | 3,013 | 135,675 | 209,487 | Jun 26 |
| Barrow Robert | Chief Executive Officer | Jun 25 '26 | Sale | 45.03 | 29,208 | 1,315,236 | 1,098,246 | Jun 26 |
| Karlin Daniel | Chief Medical Officer | Jun 25 '26 | Sale | 45.03 | 10,035 | 451,876 | 503,282 | Jun 26 |
| Wiley Matthew T. | Chief Commercial Officer | Jun 25 '26 | Sale | 45.03 | 2,867 | 129,101 | 174,633 | Jun 26 |
| Karlin Daniel | Chief Medical Officer | Mar 25 '26 | Sale | 18.47 | 8,018 | 148,092 | 413,317 | Mar 26 |
| Sullivan Mark | Chief Legal Officer | Mar 25 '26 | Sale | 18.47 | 10,702 | 197,666 | 271,079 | Mar 26 |
| Barrow Robert | Chief Executive Officer | Mar 25 '26 | Sale | 18.47 | 24,431 | 451,241 | 752,454 | Mar 26 |
| Karlin Daniel | Chief Medical Officer | Dec 26 '25 | Sale | 13.15 | 5,600 | 73,623 | 425,025 | Dec 29 |
| Barrow Robert | Chief Executive Officer | Dec 26 '25 | Sale | 13.15 | 25,791 | 339,072 | 778,477 | Dec 29 |
| Sullivan Mark | Chief Legal Officer | Dec 26 '25 | Sale | 13.15 | 11,276 | 148,244 | 282,576 | Dec 29 |
| Sullivan Mark | Chief Legal Officer | Sep 25 '25 | Sale | 9.77 | 11,278 | 110,186 | 293,852 | Sep 26 |
| Barrow Robert | Chief Executive Officer | Sep 25 '25 | Sale | 9.77 | 25,797 | 252,037 | 804,268 | Sep 26 |
| Karlin Daniel | Chief Medical Officer | Sep 25 '25 | Sale | 9.77 | 7,704 | 75,268 | 430,625 | Sep 26 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.